Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study

• Published in: Rheumatic & musculoskeletal diseases open Vol. 9; no. 2; p. e003029
• Main Authors: Kubo, Satoshi, Miyazaki, Yusuke, Amano, Koichi, Matsui, Kiyoshi, Kameda, Hideto, Inoue, Yoshino, Nakayamada, Shingo, Ogura, Takehisa, Kaneko, Yuko, Yamaoka, Kunihiro, Tanaka, Yoshiya
• Format: Journal Article
• Language: English
• Published: England EULAR 01.04.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: antirheumatic agents; Antirheumatic Agents - adverse effects; arthritis; Arthritis, Rheumatoid - chemically induced; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Disease; Drug dosages; Drug withdrawal; Humans; Methotrexate - adverse effects; Patients; Piperidines - adverse effects; Remission (Medicine); rheumatoid; Rheumatoid Arthritis; therapeutics; therapeutics; arthritis; antirheumatic agents; rheumatoid
• ISSN: 2056-5933; 2056-5933
• DOI: 10.1136/rmdopen-2023-003029

ObjectiveTo investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis.MethodsPatients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying antirheumatic drugs were randomly divided into two groups at baseline, and tofacitinib treatment in combination with MTX was administered to both groups. Either MTX or tofacitinib was then withdrawn if patients achieved Clinical Disease Activity Index remission at week 52. The primary outcome was the proportion of patients who sustained clinical remission at week 104.ResultsA total of 113 patients participated in this study. Among them, a total of 48 patients achieved remission at week 52. After discontinuation of tofacitinib, only 29.2% (7/24) of patients remained remission, while 50.0% (10/20) of patients, which was numerically higher but not statistically significant, sustained remission after MTX discontinuation. A greater proportion of bio-naïve patients achieved remission at week 52 and sustained low disease activity with tofacitinib discontinuation at week 104. Additionally, the patients who were able to discontinue tofacitinib without flares had lower rheumatoid factor (p=0.04) and lower anti-cyclic citrullinated peptide antibody (p=0.051) before discontinuation of tofacitinib. No severe adverse events were recorded after discontinuation of tofacitinib or MTX. In patients who relapsed after tofacitinib discontinuation, 71.4% achieved remission with resumption of tofacitinib.ConclusionsThis study implies that a blanket cessation of tofacitinib may not be suitable for all patients, given that 58% of the participants experienced relapse. However, the withdrawal of tofacitinib is unlikely to result in the acquisition of treatment-resistance.